A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Overview
- Phase
- Phase 2
- Intervention
- Brilacidin
- Conditions
- Skin Infection
- Sponsor
- Cellceutix Corporation
- Enrollment
- 215
- Locations
- 1
- Primary Endpoint
- Early clinical response
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
Detailed Description
This is a randomized, multi-center, double-blind study to evaluate the efficacy and safety of three regimens of brilacidin compared to an active control, daptomycin, in subjects with ABSSSI. Subjects must have infections that warrant intravenous therapy but may be treated as either inpatients or outpatients. Eligible subjects will be randomized to one of 4 treatment groups in a 1:1:1:1 ratio. Subjects randomized to brilacidin will receive either a single intravenous infusion (0.6 mg/kg or 0.8 mg/kg) followed by six days of once daily placebo, or a three day regimen (0.6 mg/kg on Day 1 followed by 0.3 mg/kg on Days 2 and 3) followed by 4 days of once daily placebo. Subjects randomized to daptomycin will receive 7 days of treatment. Subjects will be assessed for both clinical and microbiologic efficacy 48-72 hours after the first dose of study drug. After an assessment at Day 7-8, subjects will be again be evaluated for efficacy at Day 10-14 and via a phone contact at Day 21-28. Approximately 200 subjects randomized in a 1:1:1:1 ratio to receive one of the three brilacidin regimens or daptomycin will be evaluable. The primary efficacy outcome, early clinical response 48-72 hours after the first dose of study drug, will be determined in the Intent-to treat (ITT) population. Additional efficacy and safety analyses will be performed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provision of written informed consent
- •Be ≥ 18 and ≤ 85 years of age
- •Have one of the following types of ABSSSI:
- •A post-traumatic or post-surgical wound infection, occurring within 30 days of the trauma or surgery, characterized by purulent or seropurulent drainage from the wound and surrounding erythema, edema and/or induration of a minimum surface area of 75 cm
- •A major cutaneous abscess, characterized by a collection of pus within the dermis or deeper tissues, accompanied by erythema, edema, and/or induration of a minimum surface area of 75 cm
- •Note: patients with major cutaneous abscess will be limited to 30% of total enrollment
- •Cellulitis/erysipelas, characterized by spreading areas of erythema, edema, and/or induration of a minimum surface area of 75 cm
- •Have two or more of the following signs:
- •Purulent or seropurulent drainage or discharge
- •Heat or localized warmth
Exclusion Criteria
- •Female subjects who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study.
- •Skin or skin structure infection with any of the following characteristics:
- •Presence of an uncomplicated skin or skin structure infection, such as folliculitis, furunculosis, or minor abscess likely to respond to incision and drainage alone
- •Suspected or confirmed osteomyelitis
- •Suspected or confirmed septic arthritis
- •Suspected or confirmed infection caused exclusively by Gram-negative pathogens or by any anaerobes
- •Known hypersensitivity to daptomycin
- •Known creatinine clearance \<50 mL/min (based on the Cockcroft-Gault formula using ideal body weight)
- •Immunosuppression, defined as chronic corticosteroid use (20 mg prednisone/day or equivalent), solid organ or bone marrow transplantation, current cytotoxic chemotherapy, neutropenia (absolute neutrophil count \< 500/mm3), or known HIV infection with CD4+ count \< 200/mm3
- •Platelet count \<50 x 103/L
Arms & Interventions
Low Single Dose Brilacidin
0.6mg/kg Brilacidin IV (single dose)
Intervention: Brilacidin
High Single Dose Brilacidin
0.8mg/kg Brilacidin IV (single dose)
Intervention: Brilacidin
3-Day Regimen Brilacidin
0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 \& 3
Intervention: Brilacidin
Standard dosing regimen Daptomycin
4mg/kg Daptomycin IV daily for 7 Days
Intervention: Daptomycin
Outcomes
Primary Outcomes
Early clinical response
Time Frame: 48-72 hours after first dose of study drug
The primary efficacy outcome, early clinical response 48-72 hours after the first dose of study drug, will be determined in the ITT population. A subject will be considered a Clinical Success if 1) the lesion area has decreased by ≥20% compared to baseline and 2) no additional systemic antibacterials that are potentially effective against gram positive organisms have been administered.
Secondary Outcomes
- Clinical Response(Day 7-8; Day 10-14; Day 21-28)
- Microbiological response(48-72 hours; Day 7-8; Day 10-14)